from Yale School of Medicine
Heerfordt IM, Philipsen PA, Lerche CM, Wulf HC
The 2026 EASO pharmacotherapy update formalised this evidence by ranking tirzepatide above semaglutide for obesity management, while simultaneously supporting semaglutide as the better-documented agent for liver fibrosis improvement in metabolic dysfunction-associated steatohepatitis (MASH), based on more mature phase 3 ESSENCE trial data [1]
It is solely intended for discussion of scientific and laboratory research topics
These products may seem like cure-all wonder potions, but theyre mostly multi-vitamins with added superfood (a made up term) powder, and protein
This gradual decline differs sharply from shorter-acting weight-loss drugs that leave your system in days, not weeks